Common Adverse Events to Immunotherapies in mNSCLC

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their approaches.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior treatment.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

The California wildfires severely affected patients with cancer, requiring evacuation protocols, community support, and learning for future disaster preparedness.

The FDA granted breakthrough status to Serial CTRS, an AI tool that improves survival predictions in non–small cell lung cancer.